综合性多omics分析确定TGFA是一种新型质瘤易感基因和治疗点
Ruiqi Jiang1,2, Shaohua Tu3, Nan Ji3
1School of Pharmaceutical Sciences, Capital Medical University, Fengtai, Beijing, China.
Frontiers in neurology
|November 21, 2025
概括
转化生长因子α (TGFA) 被确定为一种与质瘤发展相关的新型基因. 向TGFA为侵袭性脑瘤的精密治疗提供了一个新的途径.
科学领域:
- 神经瘤学神经瘤学
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 质瘤是一种具有不良预后的侵袭性脑瘤.
- 目前的治疗方法和诊断生物标志物是有限的.
- 基质瘤发展背后的分子机制需要进一步阐明.
研究的目的:
- 为了确定与质瘤易感性相关的新基因.
- 为了研究这些基因在质瘤发病过程中的作用.
- 探索质瘤的潜在治疗点.
主要方法:
- 综合多学科分析,结合GWAS和eQTL数据.
- 跨组织转录全基因组关联研究 (UTMOST,FUSION,MAGMA).
- 门德尔的随机化,贝叶斯的局部化,全现象的关联研究,免疫组织化学和药物重定位.
主要成果:
- 确定了五个候选易感基因,其中转化生长因子α (TGFA) 是最强的.
- TGFA显示出显著的质瘤关联和因果关系.
- 在特定的质瘤亚型中观察到TGFA表达的升高 (WHO等级2/3,1p/19q共删除).
- 40个FDA批准的TGFA向药物被确定,其中 irinotekan显示出高结合亲和力.
结论:
- TGFA是一种新型质瘤易感基因,具有作为诊断和治疗点的潜力.
- TGFA的表达模式表明在质瘤中具有特定亚型的作用.
- 向TGFA为精密质瘤治疗提供了一个有希望的策略.
更多相关视频
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
5.9K
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.1K
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
